年代:1999 |
|
|
Volume 34 issue 6
|
|
21. |
Interaction Between Nitric Oxide and Endogenous Vasoconstrictors in Control of Renal Blood Flow |
|
Hypertension: Journal of The American Heart Association,
Volume 34,
Issue 6,
1999,
Page 1254-1254
Heike Berthold,
Armin Just,
Hartmut Kirchheim,
Heimo Ehmke,
Preview
|
|
摘要:
The level of renal blood flow (RBF) is controlled by opposing vasoconstrictor and vasodilator influences. In a recent investigation in normotensive dogs, we found that combined blockade of endothelin type A (ETA) receptors and angiotensin II formation induces marked increases in RBF that were much larger than the effects of blocking either system alone. The aim of the present study was to determine the contribution of nitric oxide (NO) to this vasodilator response. Experiments were made in 6 conscious, chronically instrumented dogs subjected to 5 different experimental treatments on separate days. Blockade of ETAreceptors alone by the selective antagonist LU 135252 had only minor effects on RBF compared with time-control experiments. Additional blockade of angiotensin II formation by angiotensin-converting enzyme inhibition with trandolaprilat caused a substantial increase of RBF by ≈50%. This vasodilation was entirely suppressed when NO formation was prevented by inhibition of NO synthase withNG-nitro-L-arginine methyl ester HCl. However, when during NO synthase inhibition renal vascular NO concentrations were clamped at control levels by infusing the NO donorS-nitroso-N-acetyl-D,L-penicillamine, the vasodilator response to combined blockade of ETAreceptors and angiotensin II formation was completely restored (&Dgr;RBF ≈60%). These results indicate that the vasodilation after combined ETAreceptor blockade and angiotensin-converting enzyme inhibition is not mediated by an increase in NO release but results from the unmasking of the tonic influence that is normally exerted by constitutively released NO. Accordingly, the tonic activity of endothelial NO synthase appears to be of major importance in the physiological regulation of renal vascular resistance by determining the vasomotor responses to endothelin and angiotensin II.
ISSN:0194-911X
出版商:OVID
年代:1999
数据来源: OVID
|
22. |
Salicylate Inhibition of Extracellular Signal-Regulated Kinases and Inducible Nitric Oxide Synthase |
|
Hypertension: Journal of The American Heart Association,
Volume 34,
Issue 6,
1999,
Page 1259-1259
Zhongyan Wang,
Peter Brecher,
Preview
|
|
摘要:
The expression of inducible nitric oxide synthase (iNOS) is a characteristic response to inflammation and can be inhibited with sodium salicylate. We used the cytokine-induced iNOS induction in cardiac fibroblasts as a model system in which to test the hypothesis that effects on mitogen-activated protein kinases (MAPKs) may explain the mechanism by which salicylate exerts its anti-inflammatory effects. Tumor necrosis factor-&agr; (TNF-&agr;) alone can induce extracellular signal-regulated kinase (ERK), p38 MAPK, and c-Jun N-terminal kinase activity in a rapid and transient manner, whereas interferon-&ggr; (IFN-&ggr;) can induce only ERK. The inhibition of either the ERK pathway or p38 MAPK activity with selective inhibitors blocked cytokine-induced iNOS protein and nitrite production. Salicylate treatment inhibited iNOS expression induced by TNF-&agr; and IFN-&ggr; and attenuated the phosphorylation of ERK by TNF-&agr; and IFN-&ggr; either alone or in combination. Salicylate had no obvious effect on the activation of p38 MAPK or c-Jun N-terminal kinase. The results showed that salicylate inhibited the phosphorylation of ERK and iNOS expression induced by cytokines in a dose-dependent manner and suggested that salicylate exerts its anti-inflammatory action in part through inhibition of the ERK pathway and iNOS induction.
ISSN:0194-911X
出版商:OVID
年代:1999
数据来源: OVID
|
23. |
Elements of a Paracrine Tubular Renin-Angiotensin System Along the Entire Nephron |
|
Hypertension: Journal of The American Heart Association,
Volume 34,
Issue 6,
1999,
Page 1265-1265
Andreas Rohrwasser*,
Terry Morgan*,
Harrison Dillon,
Ling Zhao,
Christopher Callaway,
Elaine Hillas,
Shuhua Zhang,
Tong Cheng,
Tadashi Inagami,
Kenneth Ward,
Daniel Terreros,
Jean-Marc Lalouel,
Preview
|
|
摘要:
The renin-angiotensin system is a major regulator of body sodium, predominantly through the actions of intrarenal angiotensin II of unclear origin. We show that polarized epithelium of the proximal tubule synthesizes and secretes angiotensinogen at its apical side and that the protein can be detected in urine as a function of dietary sodium. Furthermore, we demonstrate that renin is expressed and secreted in a restricted nephron segment, the connecting tubule, also in a sodium-dependent fashion. A paracrine renin-angiotensin system operating along the entire nephron may contribute to long-term arterial pressure regulation by integrating distant tubular sodium-reabsorbing functions.
ISSN:0194-911X
出版商:OVID
年代:1999
数据来源: OVID
|
24. |
Thiol Protein Defect in Sodium-Lithium Countertransport in Subset of Essential Hypertension |
|
Hypertension: Journal of The American Heart Association,
Volume 34,
Issue 6,
1999,
Page 1275-1275
Paul Mead,
Robert Wilkinson,
Trevor Thomas,
Preview
|
|
摘要:
There is probably a heterogeneous etiology for essential hypertension (EHT), and abnormal erythrocyte sodium-lithium countertransport (Na/Li CT) is common in a subgroup of patients with a strong family history of hypertension and cardiovascular disease (EHT-FH patients). The aim of this study was to test the hypothesis that altering a membrane thiol protein could mimic the abnormal Na/Li CT observed in the patients and that a more refined understanding of the mechanism of abnormal Na/Li CT would facilitate a clearer identification of a subgroup of patients with a homogeneous biochemical abnormality. Na/Li CT kinetics were determined in untreated erythrocytes and after thiol group alkylation withN-ethylmaleimide (NEM). Compared with normal control erythrocytes, untreated erythrocytes from EHT-FH patients had a lowKmof Na/Li CT, with a high ratio of maximum velocity toKm. This kinetic pattern was reproduced in normal erythrocytes by treatment with NEM in sodium-free medium. The same treatment in EHT-FH erythrocytes caused a markedly abnormal effect with an increase in maximum velocity, indicating an increase in transporter turnover in contrast to the increase in sodium affinity seen in normal control erythrocytes. Frequency distributions of these kinetic changes showed a subgroup of ≈75% of EHT-FH patients with abnormal kinetic changes with NEM. Therefore, the key Na/Li CT thiol group that is very reactive to NEM and causes the abnormal Na/Li CT in a subgroup of hypertensive patients may be a useful intermediate phenotype for a disease group within the syndrome of EHT. The single flux assay of Na/Li CT at 140 mmol/L sodium poorly discriminates this group. Identification of the thiol protein involved may lead to a molecular explanation of the altered membrane function in this subgroup of patients.
ISSN:0194-911X
出版商:OVID
年代:1999
数据来源: OVID
|
25. |
Effect of the HMG-CoA Reductase Inhibitors on Blood Pressure in Patients With Essential Hypertension and Primary Hypercholesterolemia |
|
Hypertension: Journal of The American Heart Association,
Volume 34,
Issue 6,
1999,
Page 1281-1281
Nicola Glorioso,
Chiara Troffa,
Fabiana Filigheddu,
Francesco Dettori,
Aldo Soro,
Paolo Parpaglia,
Stefano Collatina,
Marco Pahor,
Preview
|
|
摘要:
Certain hydroxymethylglutaryl coenzyme A reductase inhibitors, ie, statins, may cause vasodilation by restoring the endothelial dysfunction that frequently accompanies hypertension and hypercholesterolemia. Several studies have found that a blood pressure reduction is associated with the use of statins, but conclusive evidence from controlled trials is lacking. After an 8-week placebo and diet run-in period, 30 persons with moderate hypercholesterolemia and untreated hypertension (total cholesterol 6.29±0.52 mmol/L, systolic and diastolic blood pressure 149±6 and 97±2 mm Hg) were randomized in a double-blind manner to placebo or pravastatin (20 to 40 mg/d) in a crossover design. In 25 participants who completed the 32-week trial, pravastatin decreased total and LDL cholesterol (both −1.09 mmol/L,P=0.001), systolic and diastolic blood pressure (−8 and −5 mm Hg, bothP=0.001), and pulse pressure (−3 mm Hg,P=0.011) and blunted the blood pressure increase caused by the cold pressor test (−4 mm Hg,P=0.005) compared with placebo. It also reduced the level of circulating endothelin-1 (P=0.001). The blood pressure results were virtually unchanged in stratified analyses according to gender and age and in intention-to-treat analyses that included the 5 patients who dropped out of the study. When the participants were taking either placebo or pravastatin, blood pressure was not significantly correlated with total or LDL cholesterol or with circulating endothelin-1. Pravastatin decreases systolic, diastolic, and pulse pressures in persons with moderate hypercholesterolemia and hypertension. This antihypertensive effect may contribute to the documented health benefits of certain statins.
ISSN:0194-911X
出版商:OVID
年代:1999
数据来源: OVID
|
26. |
Step-Down of Enalapril Treatment for Arterial Hypertension |
|
Hypertension: Journal of The American Heart Association,
Volume 34,
Issue 6,
1999,
Page 1287-1287
José González-Juanatey,
Antonio Reino,
José García-Acuña,
Carlos González-Juanatey,
Luis Valdes,
José Cabezas-Cerrato,
Preview
|
|
摘要:
Enalapril treatment (20 mg every 12 hours) of 24 patients with essential hypertension and left ventricular (LV) hypertrophy established normal blood pressures after 8 weeks, and after 5 years, it had reduced LV mass index by 39% (from 148±34 to 90±16 g/m2) and had normalized LV structure and function and QT dispersion. Stepwise reduction of the enalapril dosage from 40 to 30, 20, 10, and 5 mg/d during the eighth year caused no significant change in blood pressure, LV structure, LV systolic function, or QT dispersion, which all likewise remained unaltered during an additional 2-year period of the 5-mg/d regimen. We conclude that for hypertensive patients in whom prolonged treatment with high doses of enalapril has normalized blood pressure, LV structure, LV function, and QT dispersion, the dose may be reduced as much as 8-fold without detriment to cardiovascular control. The use of smaller doses is evidently advantageous from the point of view of health costs.
ISSN:0194-911X
出版商:OVID
年代:1999
数据来源: OVID
|
27. |
Effects of the Nonpeptide V1Vasopressin Receptor Antagonist SR49059 in Hypertensive Patients |
|
Hypertension: Journal of The American Heart Association,
Volume 34,
Issue 6,
1999,
Page 1293-1293
Marc Thibonnier,
Ahmad Kilani,
Mahboob Rahman,
Tina DiBlasi,
Kelly Warner,
Michael Smith,
Anne Leenhardt,
Rémi Brouard,
Preview
|
|
摘要:
We assessed the clinical and pharmacological profile of the orally active V1vascular vasopressin (AVP) receptor nonpeptide antagonist SR49059 (SR) during the osmotic stimulation of AVP release in hypertensive patients. In a double-blind crossover-versus-placebo study, 24 untreated stage I or II essential hypertensive patients (12 whites and 12 blacks) received a single 300 mg oral dose of SR 2 hours before the stimulation of AVP secretion with a 5% hypertonic saline infusion. Hemodynamic, humoral, and hormonal parameters were monitored for up to 28 hours after drug administration. SR did not alter blood pressure or heart rate before the saline infusion and did not reduce the blood pressure increment induced by the hypertonic saline infusion. However, the blood pressure peak at the end of the hypertonic saline infusion was slightly lower in the presence of SR (P=0.04). Heart rate was significantly faster between 4 and 6 hours after SR administration (P=0.02). The rise in plasma sodium and osmolality triggered by the saline infusion was not modified by SR, but AVP release was slightly greater in the presence of SR (P<0.0003). AVP-induced aggregation of blood platelets in vitro was significantly reduced by SR, with a peak effect 2 hours after drug administration that coincided with the SR peak plasma concentration. Plasma renin activity and aldosterone before and after the saline infusion were not modified by SR. Urine volume and osmolality were not altered by SR administration. SR effects were similar in the 2 ethnic groups as well as in salt-sensitive versus salt-resistant patients. In a situation of AVP osmotic release and volume expansion in hypertensive patients, a single oral dose of the V1vascular AVP receptor nonpeptide antagonist SR49059, which is able to block AVP-induced platelet aggregation, exerts a transient vasodilation effect that is not associated with a sustained blood pressure reduction. SR49059 is a pure V1vascular receptor antagonist that is devoid of V2renal receptor actions.
ISSN:0194-911X
出版商:OVID
年代:1999
数据来源: OVID
|
28. |
AT1Receptors Mediate Excitatory Inputs to Rostral Ventrolateral Medulla Pressor Neurons From Hypothalamus |
|
Hypertension: Journal of The American Heart Association,
Volume 34,
Issue 6,
1999,
Page 1301-1301
Tatsuya Tagawa,
Roger Dampney,
Preview
|
|
摘要:
Angiotensin II type 1 (AT1) receptors are located on pressor neurons in the rostral ventrolateral medulla, and their activation results in an increase in arterial pressure. However, the normal role of these AT1receptors in cardiovascular regulation is unknown. In this study, we tested the hypothesis that these receptors mediate synaptic excitation of rostral ventrolateral medullary pressor neurons in response to activation of the hypothalamic paraventricular nucleus. In anesthetized rats, microinjections of the &ggr;-aminobutyric acid receptor antagonist bicuculline were made into the paraventricular nucleus; this injection causes activation of the nucleus as a consequence of disinhibition. The pressor and sympathoexcitatory responses evoked by paraventricular nucleus activation were significantly reduced (by ≈40% to 50%) after microinjection of the specific AT1receptor antagonists losartan or L-158,809 into the rostral ventrolateral medulla on the ipsilateral, but not contralateral, side. These responses were reduced to a similar degree after microinjections of the neuroinhibitory compound muscimol into the ipsilateral, but not contralateral, rostral ventrolateral medulla. However, bilateral microinjections of the glutamate receptor antagonist kynurenic acid into the rostral ventrolateral medulla had no effect on the responses evoked from the paraventricular nucleus. Conversely, bilateral microinjections of kynurenic acid into the rostral ventrolateral medulla virtually abolished the somatosympathoexcitatory reflex, whereas bilateral microinjections of losartan or L-158,809 had no effect on this reflex. The results indicate that excitatory synaptic inputs to pressor neurons in the rostral ventrolateral medulla arising from activation of the paraventricular nucleus are mediated predominantly by AT1receptors.
ISSN:0194-911X
出版商:OVID
年代:1999
数据来源: OVID
|
29. |
HypertensionOnline: December 1999 |
|
Hypertension: Journal of The American Heart Association,
Volume 34,
Issue 6,
1999,
Page 1308-1308
Edward Frohlich,
Preview
|
|
ISSN:0194-911X
出版商:OVID
年代:1999
数据来源: OVID
|
|